This week, 10 medical innovation companies completed a new round of financing: among them, Diyingga Technology completed several hundred million yuan in Series C financing; Wuzhensong Pharmaceutical completed tens of millions of yuan in angel round financing; Likai Technology completed nearly 500 million yuan in Series D financing. In addition, cutting-edge sectors such as brain-computer interfaces, oncolytic vaccines, non-addictive analgesics, and phage technology are also receiving capital injections. Welcome to learn more!

---

1. Diyingga Technology completed hundreds of millions of yuan in Series C financing, accelerating the construction of a new ecosystem for digital and intelligent pathology

Recently, Hangzhou Diyingga Technology officially announced the completion of a Series C financing round worth several hundred million yuan, jointly invested by well-known institutions such as Fengyu Capital, Yuhang Guotou, Betta Fund, and Zhejiang Zhejiang Xian’an Investment. After the financing was completed, the company’s valuation reached several hundred million US dollars, fully confirming the capital market’s long-term recognition of the value of leading medical AI projects with hard technology attributes. As a core player filling the domestic pathology resource supply gap and driving the digital transformation of the pathology industry, Diyinga was established in 2017 and has been deeply involved in foundational digital pathology technologies and AI pathology algorithms for nearly 20 years. It is one of the few domestic digital pathology service providers with full-chain, zero-bottleneck innovation capabilities. Currently, its full range of commercialized products has been deployed in over 1,500 medical institutions at all levels nationwide, with core business annual revenue growth consistently above 100% for many consecutive years. It has also established deep cooperation with many top global pharmaceutical companies and international pathology institutions. Relying on the fully self-developed DeepPathAI pathology vertical large model foundation, Diyinga has built a fully closed-loop digital pathology platform covering slicing scanning, AI-assisted diagnosis, full-process quality control, and new drug development companion detection. It has already clearly implemented paid value in two core scenarios: clinical assisted diagnosis and treatment and innovative drug R&D. After this round of financing, the company will focus on large model iteration and global compliance layout, and will launch a new round of financing to promote global product rollout.

---

2. Wuzhinsong Pharma completed tens of millions of yuan in angel round financing, accelerating the development of a new generation ultra-long-acting peptide drug platform

On July 28, Wuzhen Song Pharmaceuticals, a key incubator company from Shenzhen Bay Laboratory focused on developing innovative therapies for metabolic diseases, officially announced the completion of an angel round financing of tens of millions of RMB. This round was led by Hetang Venture Capital, with participation from Star Sky Capital, Tylen Capital, Blue Ocean Capital, and renowned entrepreneur Mr. Shen Yousheng.

It is understood that the funds raised in this round will be directed toward advancing two core businesses: on one hand, supporting the completion of preclinical studies for its first core pipeline, TPM004, the entire IND application process, and subsequent Phase I trial subject enrollment, safety and preliminary efficacy evaluations, accelerating the clinical launch of candidate molecules.

On the other hand, the company will iterate and upgrade its fully independently developed PepTetris™ ultra-long-acting peptide technology platform, complete pilot production adaptation verification and improve the underlying patent system, further strengthening technical barriers.

Currently, the total number of metabolic chronic disease patients in China has exceeded 300 million. Traditional peptide hypoglycemic and weight-loss drugs generally suffer from short half-lives and the need for high-frequency injections, making clinical demand for peptide products with ultra-long dosing cycles extremely urgent. The investors stated that this round of investment focuses on ultra-long-acting peptides, a high-potential niche track. The core R&D team of Wuzhen Song Pharmaceuticals comes from the Shenzhen Bay Laboratory peptide drug frontier research group, with over ten years of experience in drug-specific development, and has completed pre-validation of multiple candidate molecules. Subsequent companies will focus on major indications such as diabetes, non-alcoholic fatty liver, and obesity, launching highly adherent locally innovative metabolic disease treatment solutions to fill technological gaps in the domestic field.

---

3. Shunao Technology completes angel round financing worth tens of millions, promoting the localization of brain-computer interface technology

Recently, domestic brain-computer interface medical innovation company Shunao Technology (Hangzhou Shunao Zhilian Technology Co., Ltd.) announced the completion of an angel round financing worth tens of millions. This round was jointly invested by Zhejiang Torch Center, Junyi Capital, and Pan’an Urban Construction Group. The post-investment valuation exceeded 130 million yuan, with the next round expected to exceed 200 million yuan.

Tree Brain Technology is one of the few domestic brain health companies that simultaneously masters self-developed underlying algorithms for EEG and magnetoencephalography (MEG). Its founder, Kan Jing, holds a PhD in computer science from the University of York in the UK, has nearly 20 years of experience in brain magnetic signal reconstruction, and was founded through the Peking University Institute for Advanced Information Technology. The company has built a dual technology route of “EEG screening + advanced MEG diagnosis.” Its core product, the BrainTree® AI brain disease risk risk intelligent screening and assessment system, is equipped with its self-developed QEEG EEG analysis algorithm. Brain health assessments can be completed in 7 minutes with over 95% accuracy, covering early screening for Alzheimer’s, depression, anxiety, attention deficit, and other conditions, suitable for hospitals, health checkups, campuses, and wellness care scenarios. In high-end diagnostics, the company independently developed a full-category MEG magnetoencephalography supporting algorithm solution, providing a full suite of software services for signal noise reduction, brain region imaging, and lesion tracing, breaking the long-standing monopoly of imported MEG analysis systems. Currently, the company has obtained 2 Class II medical device certificates, 18 invention patents, and 29 software copyrights, with products entering multiple medical institutions for market sales. This round of financing will be used for multimodal medical large model iteration, multi-center clinical validation, device registration, and supply chain system construction, accelerating the integration of a full-chain brain health diagnosis and treatment system of “screening—diagnosis—treatment—intervention,” and promoting the commercialization of domestic brain-computer interfaces and magnetoencephalography technologies.

---

4. Shanghai Likai Technology completes nearly 500 million yuan in Series D financing, further upgrading the competitiveness of domestic innovative devices

Recently, Shanghai Likai Technology, a core player in the domestic high-end neurointerventional medical device sector, officially announced the completion of nearly 500 million yuan in Series D financing. This round was jointly led by Shanghai Kechuang Group and Minjin Investment, with participation from well-known investment institutions including Taiping Private Equity Fund, Shenzhen Capital Group, Tongshang Venture Capital, Huatai Zijin, and Shanghai Waigaoqiao Group, with several existing shareholders continuing to make additional investments. This round of financing is also the leading single industry-level financing event disclosed in the domestic stroke intervention sector this year. Founded in 2019, Likai Technology focuses on the research, development, production, and sales of neurointerventional medical devices, with a product pipeline covering three major areas: hemorrhage, ischemia, and access therapy. Relying on a dual-driven model of “internal independent R&D + external global BD expansion,” the company independently controls core process and supply chain resources, building four foundational technology platforms: catheters, guidewires, balloons, and brackets. To date, the company has obtained 18 NMPA Class III medical device registration certificates, 1 FDA 510(k) certification, and 1 CE certification, making it one of the few platform-based enterprises in China with full product series and full-chain industrialization capabilities for neurointerventional products. In February 2026, its flagship therapeutic product, Cyllene intracranial vascular stent, was officially approved for launch, marking the company’s successful entry into the high-value interventional treatment field based on its gateway products. In terms of commercialization, the company has established a sales network covering 31 provinces nationwide, with products entering over 2,200 hospitals. Its core product, Locaste 088 delivery catheter, holds the top domestic market share, Tarvos micro guidewire remains the top domestic product in market share, and Juewa OTW intracranial balloon dilation catheter won the Group A bid in the 27-province alliance procurement. In addition, the company’s wholly-owned subsidiary Jiangsu Likai has settled in the Jiangyin 121 Future Industrial Park, completing the construction of a 7,000-square-meter clean production workshop. Core products such as intracranial thrombosis aspiration catheters have been 100% localized, with an expected annual output value exceeding 50 million yuan. This round of financing will focus on core pipeline iterative R&D, expansion of new scenarios for rare stroke diseases, clinical implementation of full-cycle innovative pipelines, capacity base upgrades meeting FDA/CE standards, and the establishment of overseas clinical registration and commercialization systems, creating a diversified growth model of “deep local penetration + overseas incremental breakthroughs.”

---

5. New Carrier Biotech completes tens of millions of yuan in Series A financing, leading innovation in phage applications

On July 27, Shandong New Route Biotechnology Co., Ltd. officially announced the completion of tens of millions of yuan in Series A financing. This round was led by leading private equity firm CMB International Capital, with Yida Capital, a leading investment platform in the hard technology sector, as a part-time investor, and Dianshi Capital as the exclusive financial advisor. The funds raised will be specifically used for upgrading the bacteriophage library of resistant bacteria, building overseas compliance systems, and expanding global business. Founded in 2018 and headquartered in Weifang, Shandong, New Airlines Biotech is one of the earliest benchmark companies in China to achieve large-scale mass production of bacteriophages. It has now established the world’s largest bacteriophage R&D and production center, relying on its independently developed full-chain phage resource utilization platform, covering a full-stack technical capability from pathogen strain isolation, high-throughput precise screening, formulation stability optimization to scenario-based implementation. Against the backdrop of stricter global antibiotic restrictions and bans, the commercialization window for bacteriophages as a core antibiotic alternative has fully opened. According to industry estimates, the global market for bacteriophage feed additives will have a compound annual growth rate of over 22% over the next five years. New Route Biotech has been deeply involved in the antibiotic reduction track in livestock farming for many years, having built multiple independent core databases covering resistant bacteria and strain characteristics from farming, forming a comprehensive product system covering multiple scenarios such as livestock and poultry health and environmental disinfection. It has cumulatively partnered with over 60 domestic top 100 livestock enterprises, and its products have been exported to overseas markets such as Europe, America, and Southeast Asia. All investors highly recognize New Airline Biotech’s track positioning advantages and technological implementation capabilities, and will provide multi-dimensional empowerment in industry, capital, and resources to help domestic phage technology go global.

---

6. Xinniu Biotech completes over 10 million yuan in angel round financing, accelerating clinical advancement of oncolysis vaccine platform

Recently, Xinniu Biotech announced the completion of an angel round financing of over 10 million RMB, led by Penglai Capital, with funds to advance clinical development of core products and upgrade its technology platform. Founded in December 2021, ChipBull Biotech is dedicated to developing therapeutic cancer vaccines based on smallpox virus vectors that have dual oncolytic and immune-activating functions. The company has built a gene modification platform with independent intellectual property rights—the “Arrow of Apollo®”—which, through multiple genetic engineering processes, enables viruses to directly kill tumor cells while continuously inducing anti-tumor immune responses, forming a new generation of immunotherapy platform combining the features of oncolytic viruses and therapeutic cancer vaccines. As a vector, the variolar virus has unique advantages, with a genome volume of about 190 kb, capable of carrying multiple exogenous genes, and possessing natural epithelial cell targeting, making it especially suitable for targeting solid tumors derived from epithelial, which account for over 80% of all cancer cases. The company is advancing its product pipeline around universal and personalized cancer vaccines and next-generation precision therapeutic protein delivery oncolytic viruses, with core products already in clinical stages. The founding team has deeply cultivated the field of oncolytic viruses, having published important research results in Cancer Cell and received BD support from multinational pharmaceutical companies such as Pfizer, Roche, and Astellas, accumulating extensive international industrial transformation experience. Lead investor Penglai Capital focuses on the cell and gene therapy sector, adopting a strategy of “invest early, invest small, invest in innovation.” Lü Yun, founder of Penglai Capital, stated that the “Apollo Arrow” platform fully demonstrates the targeting and payload advantages of the smallpox virus, and its delivery payload is also highly differentiated.

---

7. Nanjing Qingpu Bio completed approximately 600 million yuan in Series C financing, accelerating the development of innovative analgesic drugs

Recently, Nanjing Qingpu Biotechnology Co., Ltd. officially announced the completion of a Series C equity financing round totaling approximately 600 million yuan. This round was jointly led by the Medical Health Special Fund under Jiangsu Gaotou, with multiple leading pharmaceutical industry capital and innovative drug sector funds participating. All existing shareholders in previous rounds made large additional investments, with Kaicheng Capital serving as the exclusive financial advisor for this transaction. As one of the fastest-growing segments in the innovative drug sector in recent years, the number of chronic pain patients in China has surpassed 300 million, and the global total number of chronic pain patients exceeds 1 billion. The addictive nature and respiratory depression of traditional opioid analgesics have become a severe public health burden, and clinical demand for non-addictive innovative analgesic therapies continues to surge. Founded in 2017, Qingpu Biotech is a rare domestic platform company focused on the full-chain development of new non-addictive analgesic drugs. Its pipeline covers multiple unmet clinical scenarios such as postoperative acute pain, cancer pain, and neuralgia. The first product, Putannin, ® has already received marketing approval from regulatory authorities in both China and the United States, and the second globally pioneering analgesic molecule, QP-6211, has received formal CDE approval for new drug marketing applications, potentially filling the clinical gap in the global field of moderate to severe non-addictive analgesia. Another core pipeline is about to enter Phase III clinical trials. All funds raised in this round will be used for clinical development in later pipelines, overseas multicenter clinical trial applications, and preliminary commercialization system setup. Investors generally believe that Qingpu Bio’s technology platform, pipeline progress, and industry transformation team are all among the world’s top tier, and are expected to help China lead the world in non-addictive analgesics.

---

8. Huawei Smart Diagnostics completes Series A financing, accelerating the commercialization of early cancer screening technology

On July 23, Huawei Zhijian Medical Technology (Harbin) Co., Ltd. officially announced the completion of its Series A equity financing. This round was led by Heilongjiang Province Keli High-Tech Industry Investment Co., Ltd., a state-owned state-owned science and technology innovation investment platform affiliated with Heilongjiang Province. This is a recent representative financing event in the local life sciences field of Heilongjiang Province. Huawei Intelligent Inspection is a key technology enterprise incubated in Harbin’s tech market. Just one year after its founding, it completed a crucial leap from technological breakthroughs to preliminary commercial validation: its independently developed core technology platform, “DNA Methylation Fluorescent Ultrasensitive Joint Inspection Technology (MePlex),” has entered the substantive examination stage for national invention patents. This technology efficiently captures free tumor DNA fragments using only peripheral blood samples. Compared to traditional CT imaging methods, it can detect tumors in six major high-incidence areas—lung, liver, stomach, intestines, bile ducts, and pancreas up to one year earlier—covering over 65% of high-incidence cancer cases in China. The entire testing process takes only 5 hours, and it enables high-frequency continuous monitoring of small residual lesions (MRD) after surgery, providing dynamic evidence-based support for optimizing clinical treatment plans. Currently, the company has established research and transformation collaborations with top clinical centers such as Peking Union Medical College Hospital, 301 Hospital, and the First Affiliated Hospital of Harbin Medical University, achieving over 5 million yuan in revenue by 2025. All funds raised in this round will be invested in advancing clinical registration, building mass production pipelines, and penetrating the market for core products, accelerating the implementation of high-accessibility early tumor screening technology. The lead investor in this round, Keli Investment, is a wholly state-owned institution under Heilongjiang New Industry Investment Group. This investment also reflects the targeted support provided by the provincial strategic emerging industry fund for the local original oncology diagnosis and treatment technology track, and will further popularize hard scientific achievements in life sciences in Northeast China to the clinical end.

---

9. Shanghai BrainTech secures tens of millions in financing, focusing on brain-computer interface rehabilitation

Recently, Shanghai Neurooji Medical Technology Co., Ltd. officially announced the completion of a ten-million-yuan angel++ round financing. This round is jointly funded by Lingyi Investment and Hengxu Capital, with the funds directed toward advancing clinical trials for its core closed-loop brain-machine interface rehabilitation device, Class III medical device registration applications, building mass production supply chain systems, and expanding clinical scenarios. As a leading domestic startup focused on brain-computer interface tracks for motor rehabilitation of limb paralysis, Neuroji Technology established its headquarters in Shanghai in April 2023. Its core team is deeply connected to the research resources of the Chinese Academy of Sciences, achieving seamless transition of cutting-edge technologies from laboratory to clinical application. The company has pioneered the underlying technology of “brain-spinal nerve pathway reconstruction,” specifically overcoming the common industry pain points where traditional neurorehabilitation programs have poor intervention outcomes for patients with limb paralysis caused by severe stroke and spinal cord injury. Currently, the company has achieved independent and controllable full-stack technology, possessing four core patents including targeted regulation of the lateral hypothalamic neural circuit. Its products are laid out around its self-developed BCI-LHA-DBS platform, forming a pipeline matrix consisting of closed-loop neural regulation complete devices, high-precision implanted electrode consumables, and intelligent rehabilitation training workstations, covering the entire clinical intervention process. It is estimated that by 2029, the domestic brain-computer interface market will reach 6.8 billion yuan, with medical rehabilitation being the most certain core growth sector, and there is still a significant supply gap for domestically produced high-end related equipment. After this round of financing, Neuroji Technology will further accelerate the transformation of its achievements and promote the localization and substitution of high-end neuromodulation medical devices.

---

10. Koleso Medical completes seed round financing and launches the IIT for exosome orthopedic innovative drugs

Recently, Shanghai Kelaiso Medical Technology Co., Ltd., which focuses on exosome orthopedic innovative therapies, officially announced the completion of a seed round financing worth several million yuan. This round was led by Tongmengzhe (Shenzhen) Pharmaceutical Venture Capital, with multiple investment institutions with pharmaceutical industry backgrounds participating. All funds raised will be used to advance core pipeline clinical research and build an innovative drug compliance system. Currently, the number of osteoarthritis patients in China exceeds 130 million. Current clinical treatment plans can only relieve pain symptoms, and there is no effective intervention method to block degenerative cartilage lesions, leaving a significant gap in clinical demand. Exosomes, with their low immunogenicity, wide target modification space, and high safety in vivo delivery, are recognized as the most promising next-generation technology pathway in orthopedic regenerative medicine. Previously, the industry was long constrained by immature large-scale production processes and unclear regulatory paths. In recent years, with the domestic CDE successively issuing guidelines for the R&D and application of innovative exosome drugs, the industry’s compliance paths have become thoroughly clear, and the sector has officially entered a period of clinical translation explosion. After this round of financing is completed, Kleiso will lead with Taicang First People’s Hospital as the lead unit, collaborating with multiple domestic tertiary orthopedic centers to launch core pipeline multi-center IIT research and simultaneously advance preliminary preparations for IND applications. Relying on a full-chain technology system previously built with industry partners such as Baibi Sino, the company has completed a closed-loop construction from cell engineering modification and large-scale exosome purification to full-chain quality control, officially stepping from the platform technology validation stage into the fast track of clinical translation. Subsequent companies will accumulate clinical evidence along established paths, advance pipeline applications, and simultaneously explore multi-field applications of exosomes, aiming to become a benchmark technology platform enterprise in the orthopedic exosome sector.

END

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.